SURE

Conference or Workshop Item

Mdegela, Mselenge (2023) Development of Scalable, Electronic Health Record (EHR)-Based Screening for Undiagnosed Systemic Mastocytosis: PREDICT-SM. In: AAAAI Annual Meeting, 2023, 24-27th Feb 2023, San Antonio, TX, USA.

Mdegela, Mselenge (2022) AZURE: A Phase 1/2 Study of BLU-263 as Monotherapy and in Combination With Azacitidine in Patients With Advanced Systemic Mastocytosis. In: 64th ASH Annual Meeting and Exposition, 10-13 Dec 2022, New Orleans, LA, USA..

Mdegela, Mselenge (2022) A phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations. In: American Association of Clinical Oncology, 03-07 Apr 2022.

Mdegela, Mselenge (2022) BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models. In: American Association for Cancer Research (AACR), 08-13th Apr 2022, New Orleans.

Mdegela, Mselenge (2022) Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA in the phase 1/2 SYMPHONY study. In: American Association for Cancer Research (AACR), 08-13th Apr 2022, New Orleans.